Send us a text

• Introduction of InvivoSciences: Ayla Annac, co-founder and CEO of InvivoSciences, discusses the company's focus on developing therapies for cardiovascular and cardiometabolic diseases through innovative precision medicine technology.

• Personal Motivation: Ayla’s passion for addressing cardiovascular diseases stems from the personal loss of her father to heart disease at a young age, which motivated her to pursue solutions in this medical field.

• Technological Innovation: InvivoSciences utilizes a proprietary platform named Cordia for drug discovery and to identify subpopulations that match specific drugs, enhancing the effectiveness and safety of medications.

• Challenges and Perseverance: Ayla highlights the financial and industry challenges in drug development, emphasizing the need for increased investment and collaboration within the sector to bring innovative treatments to market.

• Vision and Future Goals: Ayla's mission extends beyond her company to push for a broader adoption of precision medicine in cardiovascular treatment, aiming to develop effective drugs that can significantly reduce the impact of heart diseases globally.